Tyler John Southwell, MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

None Reported

None Reported

A Phase IIB, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, reactogenicity and immunogenicity of the XXXX investigational vaccine XXXX when administered intramuscularly according to a 0, 2 month schedu
Date: 01 2017

A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF XXXXX IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
Date: 01 2017

A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of XXXXX in Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment who have Inadequate Glycemic Control (SAN
Date: 01 2017

A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of XXXXX in Patients with Type 2 Diabetes Mellitus and Severe Renal Impairment who have Inadequate Glycemic Control (S
Date: 01 2017

A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of XXXXX in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Alone or in Addition to Oral Anti
Date: 01 2017

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of XXXXX Added to XXXXX in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on XXXXX
Date: 01 2017

A SINGLE-ARM, PHASE III, OPEN-LABEL, MULTICENTER, STUDY IN WOMEN AGED 18-35 YEARS OF THE CONTRACEPTIVE EFFICACY AND SAFETY OF XXXXX CONTRACEPTIVE VAGINAL GEL
Date: 01 2017

An 8-week, double-blind, placebo-controlled parallel group study to evaluate the effect two different doses of XXXXX on intravaginal ejaculatory latency time (IELT) and patient-reported outcomes in men with lifelong premature ejaculation (PE)
Date: 01 2017

AN OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE III STUDY TO COMPARE THE IMMUNOGENICITY, EFFICACY, AND SAFETY OF XXXXX TO XXXXX IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS (G
Date: 01 2017

Observational study on user satisfaction with the levonorgestrel intrauterine delivery system XXXX in new contraceptive users and after switching from another contraceptive method
Date: 01 2017